Lung preservation: The importance of endothelial and alveolar type II cell integrity

Annals of Thoracic Surgery

Volumn 62, Issue 1, 1996, Pages 302-314

  Novick, Richard J ^a   Gehman, Kenneth E ^a   Ali, Imtiaz S ^a   Lee, John ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIUM; HUMAN; LUNG ALVEOLUS CELL; LUNG TRANSPLANTATION; ORGAN PRESERVATION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

EID: 0030200241     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/0003-4975(96)00333-5     Document Type: Review

References (141)

1. 1. Novick RJ, Menkis AH, McKenzie FN. New trends in lung preservation: a collective review. J Heart Lung Transplant 1992;11:377-92.
2. 2. Kirk AJB, Colquhoun IW, Dark JH. Lung preservation: a review of current practice and future directions. Ann Thorac Surg 1993;56:990-1000.
3. 3. Cooper JD, Vreim CE. Biology of lung preservation for transplantation. Am Rev Respir Dis 1992;146:803-7.
4. 4. Date H, Trulock EP, Arcidi JM, Sundaresan S, Cooper JD, Patterson GA. Improved airway healing after lung transplantation: an analysis of 348 bronchial anastomoses. J Thorac Cardiovasc Surg 1995;110:1424-33.
5. 5. Shackleton CR, Ettinger SL, McLoughlin MG, Scudamore CH, Miller RR, Keown PA. Effect of recovery from ischemic injury on class I and class II MHC antigen expression. Transplantation 1990;49:641-3.
6. 6. Serrick C, Adoumie R, Giaid A, Shennib H. The early release of interleukin-2, tumor necrosis factor-alpha and interferon-gamma after ischemia reperfusion injury in the lung allograft. Transplantation 1994;58:1158-62.
7. 7. Shiraishi T, Mizuta T, DeMeester SR, et al. Effect of ischemic injury on subsequent rat lung allograft rejection. Ann Thorac Surg 1995;60:947-51.
8. 8. Pham SM, Yoshida Y, Aeba R, et al. Interleukin-6, a marker of preservation injury in clinical lung transplantation. J Heart Lung Transplant 1992;11:1017-24.
9. 9. Hosenpud JD, Novick RJ, Breen TJ, Keck B, Daily P. The registry of the International Society for Heart and Lung Transplantation: twelfth official report - 1995. J Heart Lung Transplant 1995;14:805-15.
10. 10. Egan TM, Boychuck JE, Rosato K, Cooper JD. Whence the lungs? A study to assess suitability of donor lungs for transplantation. Transplantation 1992;53:420-2.
11. 11. Sundaresan S, Semenkovich J, Ochoa L, et al. Successful outcome of lung transplantation is not compromised by the use of marginal donor lungs. J Thorac Cardiovasc Surg 1995;109:1075-80.
12. 12. Novitzky D, Wicomb WN, Rose AG, Cooper DKC, Reichart B. Pathophysiology of pulmonary edema following experimental brain death in the Chacma baboon. Ann Thorac Surg 1987;43:288-94.
13. 13. Bittner HB, Kendall SWH, Chen EP, Craig D, Van Trigt P. The effects of brain death on cardiopulmonary hemodynamics and pulmonary blood flow characteristics. Chest 1995;108:1358-63.
14. 14. Riou B, Guesde R, Jacquens Y, Duranteau R, Viars P. Fiberoptic bronchoscopy in brain-dead organ donors. Am J Respir Crit Care Med 1994;150:558-60.
15. 15. Pison U, Seeger W, Buchhorn R, et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am Rev Respir Dis 1989;140:1033-9.
16. 16. Connell RS, Swank RL, Webb MC. The development of pulmonary ultrastructural lesions during hemorrhagic shock. J Trauma 1975;15:116-29.
17. 17. Anderson BO, Moore EE, Moore FA, et al. Hypovolemic shock promotes neutrophil sequestration in lungs by xanthine oxidase-related mechanism. J Appl Physiol 1991;71: 1862-5.
18. 18. Roumen RMH, Hendriks T, van der Ven-Jongekrijg J, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma: relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;218:769-76.
19. 19. Hasegawa S, Ritter JH, Patterson GA, et al. Expression of intercellular and vascular cell adhesion molecules and class II major histocompatibility antigens in human lungs: lack of influence by conditions of organ preservation. J Heart Lung Transplant 1995;14:897-905.
20. 20. Lefer AM, Lefer DJ. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol 1993;33:71-90.
21. 21. Horgan MJ, Wright SD, Malik AB. Antibody against leukocyte integrin (CD18) prevents reperfusion-induced lung vascular injury. Am J Physiol 1990;259:L315-9.
22. 22. Horgan MJ, Ge M, Gu J, Rothlein R, Malik AB. Role of ICAM-1 in neutrophil-mediated lung vascular injury after occlusion and reperfusion. Am J Physiol 1991;261:H1578-84.
23. 23. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990;4:2868-80.
24. 24. McEver RP. Selectins: novel receptors that mediate leukocyte adhesion during inflammation. Thromb Haemost 1991; 65:223-8.
25. 25. Bevilacqua M, Butcher E, Furie B, et al. Selectins: a family of adhesion receptors. Cell 1991;67:233.
26. 26. Janeway CA, Travers P. Immunobiology: the immune system in health and disease. New York/London: Garland/Current Biology 1994;9:13-4.
27. 27. Kelley J. Cytokines of the lung. Am Rev Respir Dis 1990; 141:765-88.
28. 28. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990;70:427-51.
29. 29. Goldblum SE, Hennig B, Jay M, Yoneda K, McClain CJ. Tumor necrosis factor α-induced pulmonary vascular endothelial injury. Infect Immun 1989;57:1218-26.
30. 30. DeMeester SR, Rolfe MW, Kunkel SL, et al. The bimodal expression of tumor necrosis factor-α in association with rat lung reimplantation and allograft rejection. J Immunol 1993;6:2494-505.
31. 31. Rolfe MW, Kunkel SL, DeMeester SR, et al. Expression of interleukin-6 in association with rat lung reimplantation and allograft rejection. Am Rev Respir Dis 1993;147:1010-6.
32. 32. Sekido N, Harada A, Watanabe Y, Mukaida N, Nakanishi I, Matsushima K. Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8. Nature 1993;365:654-7.
33. 33. Eppinger MJ, Deeb GM, Bolling SF, Ward PA. Regulatory role of IL-10 in rat lung ischemia-reperfusion injury. Surg Forum 1995;46:306-9.
34. 34. Malefyt RDW, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
35. 35. Sundaresan S, Alevy YG, Steward N, et al. Cytokine gene transcripts for tumor necrosis factor-α, interleukin-2, and interferon-γ in human pulmonary allografts. J Heart Lung Transplant 1995;14:512-8.
36. 36. Christie NA, Smith DE, Decampos KN, Slutsky AS, Patterson GA, Tanswell AK. Lung oxidant injury in a model of lung storage and extended reperfusion. Am J Respir Crit Care Med 1994;150:1032-7.
37. 37. Gee MH, Albertine KH. Neutrophil-endothelial cell interactions in the lung. Annu Rev Physiol 1993;55:227-48.
38. 38. Pillai R, Bando K, Schueler S, Zebley M, Reitz BA, Baumgartner WA. Leukocyte depletion results in excellent heart-lung function after 12 hours of storage. Ann Thorac Surg 1990;50:211-4.
39. 39. Eichacker PQ, Farese A, Hoffman WD, et al. Leukocyte CD11b/18 antigen-directed monoclonal antibody improves early survival and decreases hypoxemia in dogs challenged with tumor necrosis factor. Am Rev Respir Dis 1992;145: 1023-9.
40. 40. Kapelanski DP, Iguchi A, Niles SD, Mao HZ. Lung reperfusion injury is reduced by inhibiting a CD18-dependent mechanism. J Heart Lung Transplant 1993;12:294-307.
41. 41. Buchanan SA, Mauney MC, de Lima NF, et al. Enhanced isolated lung function after ischemia using anti-intercellular adhesion molecule antibody. J Thorac Cardiovasc Surg 1996;111:941-7.
42. 42. Steinberg JB, Mao HZ, Niles SD, Jutila MA, Kapelanski DP. Survival in lung reperfusion injury is improved by an antibody that binds and inhibits L- and E-selectin. J Heart Lung Transplant 1994;13:306-18.
43. 43. Uthoff K, Zehr KJ, Lee PC, et al. Neutrophil modulation results in improved pulmonary function after 12 and 24 hours of preservation. Ann Thorac Surg 1995;59:7-13.
44. 44. Eppinger MJ, Jones ML, Deeb GM, Bolling SF, Ward PA. Pattern of injury and role of neutrophils in reperfusion injury of rat lung. J Surg Res 1995;58:713-8.
45. 45. Ward PA, Till GO, Warren JS. Pathophysiology of leukocyte-mediated tissue injury. J Crit Care 1991;6:112-6.
46. 46. Xing Z, Kirpalani H, Torry D, Jordana M, Gauldie J. Polymorphonuclear leukocytes as a significant source of tumor necrosis factor-α in endotoxin-challenged lung tissue. Am J Pathol 1993;143:1009-15.
47. 47. Williams JH, Patel SK, Hatakeyama D, et al. Activated pulmonary vascular neutrophils as early mediators of endotoxin-induced lung inflammation. Am J Respir Cell Mol Biol 1993;8:134-44.
48. 48. Strieter RM, Kasahara K, Allen RM, et al. Cytokine-induced neutrophil-derived interleukin-8. Am J Pathol 1992;141:397-407.
49. 49. Brain SD, Williams TJ. Leukotrienes and inflammation. Pharmacol Ther 1990;46:57-66.
50. 2 metabolites and neutrophil elastase synergistically cause edematous injury in isolated rat lungs. J Appl Physiol 1986;61:2224-9.
51. 51. Horiguchi T, Harada Y. The effect of protease inhibitor on reperfusion injury after unilateral pulmonary ischemia. Transplantation 1993;55:254-8.
52. 52. Binns OAR, de Lima NF, Buchanan SA, et al. Neutrophil protease inhibitor improves pulmonary function during reperfusion after 18 hours of preservation. J Thorac Cardiovasc Surg (in press).
53. 53. Steimle CN, Guynn TP, Morganroth ML, Bolling SF, Carr K, Deeb GM. Neutrophils are not necessary for ischemia-reperfusion lung injury. Ann Thorac Surg 1992;53:64-73.
54. 54. Grosso MA, Brown JM, Viders DE, et al. Xanthine oxidase-derived oxygen radicals induced pulmonary edema via direct endothelial cell injury. J Surg Res 1989;46:355-60.
55. 55. Haniuda M, Dresler CM, Mizuta T, Cooper JD, Patterson GA. Free radical-mediated vascular injury in lungs preserved at moderate hypothermia. Ann Thorac Surg 1995;60: 1376-81.
56. 56. Su M, Chi EY, Bishop MJ, Henderson WR. Lung mast cells increase in number and degranulate during pulmonary artery occlusion/reperfusion injury in dogs. Am Rev Respir Dis 1993;147:448-56.
57. 57. Crestani B, Cornillet P, Dehoux M, Rolland C, Guenounou M, Aubier M. Alveolar type II epithelial cells produce interleukin-6 in vitro and in vivo: regulation by alveolar macrophage secretory products. J Clin Invest 1994;94: 731-40.
58. 58. Standiford TJ, Kunkel SL, Basha MA, et al. Interleukin-8 gene expression by a pulmonary epithelial cell line: a model for cytokine networks in the lung. J Clin Invest 1990;86:1945-53.
59. 59. Tsao PS, Lefer AM. Time course and mechanism of endothelial dysfunction in isolated ischemic- and hypoxic-perfused rat hearts. Am J Physiol 1990;259:H1660-6.
60. 60. Davenpeck KL, Guo JP, Lefer AM. Pulmonary artery endothelial dysfunction following ischemia and reperfusion of the rabbit lung. J Vasc Res 1993;30:145-53.
61. 61. Kimblad PO, Massa G, Sjöberg T, Steen S. Endothelial-dependent relaxation in pulmonary arteries after lung preservation and transplantation. Ann Thorac Surg 1993;56: 1329-34.
62. 62. Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979,300:1142-7.
63. 63. Gorman RR, Bunting S, Miller OV. Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 1977;13:377-88.
64. 64. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilation. J Clin Invest 1986;78:1-5.
65. 65. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987;327:524-6.
66. 66. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 1986;78: 760-70.
67. 67. Simonson MS, Dunn MJ. Endothelin: pathways of transmembrane signaling. Hypertension 1990;15:I5-12.
68. 68. Kourembanas S, Marsden PA, McQuillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest 1991;88: 1054-7.
69. 69. Mentzer SJ, Reilly JJ, DeCamp M, Sugarbaker DJ, Faller DV. Potential mechanism of vasomotor dysregulation after lung transplantation for primary pulmonary hypertension. J Heart Lung Transplant 1995;14:387-93.
70. 70. Okada M, Yamashita C, Okada M, Okada K. Contribution of endothelin-1 to warm ischemia/reperfusion injury of the rat lung. Am J Respir Crit Care Med 1995;152:2105-10.
71. 3H] acetyl-sn-glycero-3-phosphocholine, a structural analog of platelet activating factor, by vascular endothelial cells. Biochem Biophys Res Commun 1991;176:1557-64.
72. 4. Br J Pharmacol 1986;88: 595-605.
73. 73. Shaw JO, Pinckard RN, Ferrigni KS, McManus LM, Hanahan DJ. Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). J Immunol 1981;127:1250-5.
74. 74. Hamasaki Y, Mojarad M, Saga T, Tia HH, Said SI. Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. Am Rev Respir Dis 1984;129:742-6.
75. 75. Conte JV, Katz NM, Wallace RB, Foegh ML. Long-term lung preservation with the PAF antagonist BN 52021. Transplantation 1991;51:1152-6.
76. 76. Qayumi AK, Jamieson WRE, Poostizadeh A. Effects of platelet-activating factor antagonist CV-3988 in preservation of heart and lung for transplantation. Ann Thorac Surg 1991;52:1026-32.
77. 77. Hsieh HJ, Li NQ, Frangos JA. Shear stress increases endothelial platelet-derived growth factor mRNA levels. Am J Physiol 1991;260:H642-6.
78. 78. Pinsky D, Oz M, Liao H, et al. Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model. J Clin Invest 1993;92:2994-3002.
79. 79. Hoek JB. Intracellular signal transduction and the control of endothelial permeability. Lab Invest 1992;67:1-4.
80. 80. Ogawa S, Koga S, Kuwabara K, et al. Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cyclic AMP levels. Am J Physiol 1992; 262:C546-54.
81. 81. Adkins WK, Barnard JW, May S, Seibert AF, Haynes J, Taylor AE. Compounds that increase cAMP prevent ischemia-reperfusion pulmonary capillary injury. J Appl Physiol 1992;72:492-7.
82. 82. Naka Y, Chowdhury NC, Liao H, Michler RE, Stern DM, Pinsky DJ. Elevation of intracellular cAMP by a phosphodiesterase inhibitor or cAMP analogs improves vascular function in orthotopic rat lung transplants. Circulation 1994;90(Suppl 1):151.
83. 1 after lung transplantation improves early graft function. Ann Thorac Surg 1994;58:655-61.
84. 84. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991;88:4651-5.
85. 85. Kubes P, Granger DN. Nitric oxide modulates microvascular permeability. Am J Physiol 1992;262:H611-5.
86. 86. Naka Y, Chowdhury NC, Liao H, et al. Enhanced preservation of orthotopically transplanted rat lungs by nitroglycerin but not hydralazine: requirement for graft vascular homeostasis beyond harvest vasodilation. Circ Res 1995;76: 900-6.
87. 87. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia. J Clin Invest 1993;92:99-104.
88. 88. Pinsky DJ, Naka Y, Chowdhury NC, et al. The nitric oxide/cyclic GMP pathway in organ transplantation: critical role in successful lung preservation. Proc Natl Acad Sci USA 1994;91:12086-90.
89. 89. Naka Y, Roy DK, Smerling AJ, et al. Inhaled nitric oxide fails to confer the pulmonary protection provided by distal stimulation of the nitric oxide pathway at the level of cyclic guanosine monophosphate. J Thorac Cardiovasc Surg 1995; 110:1434-41.
90. 90. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977;3:23-35.
91. 91. Davidson D. NO bandwagon, yet: inhaled nitric oxide (NO) for neonatal pulmonary hypertension. Am Rev Respir Dis 1993;147:1078-9.
92. 92. Journois D, Pouard P, Mauriat P, Malhère T, Vouhé P, Safran D. Inhaled nitric oxide as a therapy for pulmonary hypertension after operations for congenital heart defects. J Thorac Cardiovasc Surg 1994;107:1129-35.
93. 93. Rich GF, Murphy GD, Roos CM, Johns RA. Inhaled nitric oxide: selective pulmonary vasodilation in cardiac surgical patients. Anesthesiology 1993;78:1028-35.
94. 94. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993;328:399-405.
95. 95. Freeman B. Free radical chemistry of nitric oxide: looking at the dark side. Chest 1994;105:79S-84S.
96. 96. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite oxidation of sulfhydryls: the cytotoxic potential of superoxide and nitric oxide. J Biol Chem 1991;266:4244-50.
97. 97. Eppinger MJ, Ward PA, Jones ML, Bolling SF, Deeb GM. Disparate effects of nitric oxide on lung ischemia-reperfusion injury. Ann Thorac Surg 1995;60:1169-76.
98. 98. Okabayashi K, Trintafillou AN, Yamashita M, et al. Inhaled nitric oxide improves lung allograft function following prolonged storage. J Thorac Cardiovasc Surg (in press).
99. 99. Adatia I, Lillehei C, Arnold JH, et al. Inhaled nitric oxide in the treatment of postoperative graft dysfunction after lung transplantation. Ann Thorac Surg 1994;57:1311-8.
100. 100. Date H, Triantafillou AN, Trulock EP, Pohl MS, Cooper JD, Patterson GA. Inhaled nitric oxide reduces human lung allograft dysfunction. J Thorac Cardiovasc Surg 1996;111: 913-9.
101. 1 in the early postoperative management of patients following bilateral lung transplantation. Circulation 1994;90(Suppl 1):637.
102. 102. Naka Y, Chowdhury NC, Oz MC, et al. Nitroglycerin maintains graft vascular homeostasis and enhances preservation in an orthotopic rat lung transplant model. J Thorac Cardiovasc Surg 1995;109:206-11.
103. 103. Yamashita M, Schmid RA, Cooper JD, Patterson GA. Nitro-prusside ameliorates lung allograft reperfusion injury. Ann Thorac Surg (in press).
104. 104. Chan BBK, Kron IL, Flanagan TL, Kern JA, Hobson CE, Tribble CG. Impairment of vascular endothelial function by high-potassium storage solutions. Ann Thorac Surg 1993; 55:940-5.
105. 105. Keshavjee SH, Yamazaki F, Yokomise H, et al. The role of dextran 40 and potassium in extended hypothermic lung preservation for transplantation. J Thorac Cardiovasc Surg 1992;103:314-25.
106. 106. Steen S, Sjöberg T, Massa G, Ericsson L, Lindberg L. Safe pulmonary preservation for 12 hours with low-potassium-dextran solution. Ann Thorac Surg 1993;55:434-40.
107. 107. Sundaresan S, Lima O, Date H, et al. Lung preservation with low-potassium dextran flush in a primate bilateral lung transplant model. Ann Thorac Surg 1993;56:1129-35.
108. 108. Date H, Matsumura A, Manchester JK, et al. Evaluation of lung metabolism during successful twenty-four hour canine lung preservation. J Thorac Cardiovasc Surg 1993;105: 480-91.
109. 109. Hardesty RL, Aeba R, Armitage JM, Kormos RL, Griffith BP. A clinical trial of University of Wisconsin solution for pulmonary preservation. J Thorac Cardiovasc Surg 1993; 105:660-6.
110. 110. Hopkinson DN, Odom NJ, Bridgewater BJM, Hooper TL. University of Wisconsin solution for lung graft preservation: which components are important? J Heart Lung Transplant 1994;13:990-7.
111. 111. Alessandrini F, Sasaki S, Said SI, Lodi R, LoCicero J. Enhancement of extended lung preservation with a vaso-active intestinal peptide-enriched University of Wisconsin solution. Transplantation 1995;59:1253-8.
112. 112. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmokinetic properties and its therapeutic efficacy. Drugs 1987;34:50-97.
113. 113. Mandell GL. ARDS, neutrophils and pentoxifylline. Am Rev Respir Dis 1988;138:1103-5.
114. 114. McDonald RJ. Pentoxifylline reduces injury to isolated lungs perfused with human neutrophils. Am Rev Respir Dis 1991;144:1347-50.
115. 115. Reignier J, Mazmanian M, Detruit H, et al. Reduction of ischemia-reperfusion injury by pentoxifylline in the isolated rat lung. Am J Respir Crit Care Med 1994;150:342-7.
116. 116. Okabayashi K, Aoe M, DeMeester SR, Cooper JD, Patterson GA. Pentoxifylline reduces lung allograft reperfusion injury. Ann Thorac Surg 1994;58:50-6.
117. 117. Novick RJ, Possmayer F, Veldhuizen RAW, Menkis AH, McKenzie FN. Surfactant analysis and replacement therapy: a future tool of the lung transplant surgeon? Ann Thorac Surg 1991;52:1194-200.
118. 118. Rooney SA. The surfactant system and lung phospholipid biochemistry. Am Rev Respir Dis 1985;131:439-60.
119. 119. Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 1982;126:332-7.
120. 120. Mason J, Williams MC. Type II alveolar cell: defender of the alveolus. Am Rev Respir Dis 1977;116:81-91.
121. 121. Hahon N, Castranova V. Interferon production in rat type II pneumocytes and alveolar macrophages. Exp Lung Res 1989;15:429-45.
122. 122. Lewis JF, Jobe AH. Surfactant and the adult respiratory distress syndrome. Am Rev Respir Dis 1993;147:218-33.
123. 123. Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991;88: 1976-81.
124. 124. Veldhuizen RAW, Lee J, Sandler D, et al. Alterations in pulmonary surfactant composition and activity after experimental lung transplantation. Am Rev Respir Dis 1993;148: 208-15.
125. 125. Erasmus ME, Petersen AH, Oetomo SB, Prop J. The function of surfactant is impaired during the reimplantation response in rat lung transplants. J Heart Lung Transplant 1994;13:791-802.
126. 126. Thomassen MJ, Antal JM, Connors MJ, Meeker DP, Wiedemann HP. Characterization of Exosurf (surfactant)-mediated suppression of stimulated human alveolar macrophage cytokine responses. Am J Respir Cell Mol Biol 1994;10:399-404.
127. 127. Novick RJ, Veldhuizen RAW, Possmayer F, Lee J, Sandler D, Lewis JF. Exogenous surfactant therapy in thirty-eight hour lung graft preservation for transplantation. J Thorac Cardiovasc Surg 1994;108:259-68.
128. 128. Novick RJ, MacDonald J, Veldhuizen RAW, et al. Evaluation of surfactant treatment strategies after prolonged graft storage in lung transplantation. Am J Respir Crit Care Med (in press).
129. 129. Erasmus ME, Petersen AH, Hofstede G, Haagsman HP, Oetomo SB, Prop J. Surfactant treatment before reperfusion improves the immediate function of lung transplants in rats. Am J Respir Crit Care Med 1996;153:665-70.
130. 130. Buchanan SA, de Lima NF, Mauney MC, et al. Intratracheal surfactant administration preserves airway compliance during reperfusion in an isolated perfused rabbit lung model. J Heart Lung Transplant 1995;14:S43.
131. 131. Strüber M, Cremer J, Harringer W, Hirt SW, Costard-Jäckle A, Haverich A. Nebulized synthetic surfactant in reperfusion injury after single lung transplantation. J Thorac Cardiovasc Surg 1995;110:563-4.
132. 132. Maccherini M, Keshavjee SH, Slutsky AS, Patterson GA, Edelson JD. The effect of low-potassium-dextran versus Euro-Collins solution for preservation of isolated type II pneumocytes. Transplantation 1991;52:621-6.
133. 133. Sasaki S, McCully JD, Palombo JD, Forse RA, LoCicero J. Lung preservation threshold in a compromised septic lung injury model. Ann Thorac Surg 1995;60:958-63.
134. 134. Homatas J, Bryant L, Eiseman B. Time limits of cadaver lung viability. J Thorac Cardiovasc Surg 1968;56:132-40.
135. 135. Egan TM, Lambert CJ, Reddick R, Ulicny KS, Keagy BA, Wilcox BR. A strategy to increase the donor pool: use of cadaver lungs for transplantation. Ann Thorac Surg 1991; 52:1113-21.
136. 136. Ulicny KS, Egan TM, Lambert CJ, Reddick RL, Wilcox BR. Cadaver lung donors: effect of preharvest ventilation on graft function. Ann Thorac Surg 1993;55:1185-91.
137. 137. Egan TM, Ulicny KS, Lambert CJ, Wilcox BR. Effect of free radical scavenger on cadaver lung transplantation. Ann Thorac Surg 1993;55:1453-9.
138. 138. D'Armini AM, Roberts CS, Griffith PK, Lemasters JJ, Egan TM. When does the lung die? I. Histochemical evidence of pulmonary viability after "death." J Heart Lung Transplant 1994;13:741-7.
139. 139. Umemori Y, Date H, Uno K, Aoe M, Ando A, Shimizu N. Improved lung function by urokinase infusion in canine lung transplantation using non-heart-beating donors. Ann Thorac Surg 1995;59:1513-8.
140. 140. Buchanan SA, de Lima NF, Binns OAR, et al. Pulmonary function after non-heart-beating lung donation in a survival model. Ann Thorac Surg 1995;60:38-46.
141. 141. Tremblay LN, Yamashiro T, DeCampos KN, et al. The effect of hypotension preceding death on the function of non-heart-beating donor lungs. J Heart Lung Transplant (in press).